MicuRx(SH:688373) Zheng Quan Zhi Xing·2025-09-04 10:18Overview - The report details the share transfer process of Shanghai Mengke Pharmaceutical Co., Ltd. (Mengke Pharma) from its shareholders JSR Limited and Best Idea International Limited to specific institutional investors [1][2][3]. Share Transfer Details - The maximum number of shares proposed for transfer is 22,946,192 shares, which represents 18,049,000 shares after the transfer, reducing JSR's holding from 5.88% to 4.70% and Best Idea's from 10.49% to 8.91% [2][3]. - The transfer method involves a price inquiry to specific institutional investors, adhering to the guidelines set by the Shanghai Stock Exchange [3][4]. Pricing Mechanism - The minimum transfer price is set at no less than 70% of the average trading price of Mengke Pharma's shares over the 20 trading days prior to August 21, 2025 [3][4]. - The final transfer price was determined to be 6.57 CNY per share, with a total subscription amount of 118,581,930 CNY [6][7]. Investor Participation - A total of 102 institutional investors received the subscription invitation, including private equity funds, public funds, securities companies, insurance companies, and qualified foreign institutional investors [5][6]. - The final allocation of shares was made to 10 institutional investors, with the total number of shares allocated being 18,049,000 [6][7]. Compliance and Verification - The report confirms that the share transfer process was conducted in compliance with relevant laws and regulations, ensuring fairness and transparency throughout the process [8][9]. - Both the transferor and transferee were verified to meet the necessary qualifications as stipulated by the regulatory guidelines [10][11].